Clinical trials are a critical and costly step in drug development. Reducing trial size while maintaining robust data is essential for accelerating market entry and managing costs.
NordicPRO‑C3™ transforms clinical trial efficiency by enabling precise pre-stratification of patients. By identifying individuals with active fibrosis who are most likely to respond to treatment, NordicPRO‑C3™ helps optimize patient selection, ensuring trials enroll the right participants from the start. This not only enhances trial success rates but also significantly reduces the number of enrollees needed—saving time, resources, and costs while increasing confidence in the therapeutic’s efficacy.
By integrating NordicPRO‑C3™ into clinical trial design, drug developers can streamline recruitment, improve study outcomes, and bring innovative fibrosis-targeted therapies to market faster.
Understanding a drug’s precise mode of action (MOA) is critical for evaluating safety, optimizing efficacy, and advancing precision medicine. However, in many cases, the exact MOA remains unclear.
NordicPRO‑C3™ provides valuable insights into MOA by detecting active fibrosis formation. A key process in disease progression and treatment response. By integrating NordicPRO‑C3™ into clinical trials, researchers gain a deeper understanding of how a drug interacts with fibrotic pathways, supporting data-driven decisions on safety, efficacy, and patient stratification.
Not all patients respond equally to treatment—many experience varying levels of efficacy and safety, while some fail to respond at all. This leads to wasted resources, ineffective care, and increased healthcare costs.
NordicPRO‑C3™ changes this by providing a powerful tool to predict treatment response in fibrotic diseases. By measuring active fibrosis, NordicPRO‑C3™ helps identify patients who are most likely to benefit from specific therapies. This enables clinicians to make informed treatment decisions, reduces unnecessary treatments, and supports reimbursement strategies.
Effective drug development requires real-time insights into treatment efficacy and pharmacodynamic effects to ensure therapies are working as intended. Traditional endpoints often fail to capture early dynamic changes in fibrosis, delaying crucial adjustments in clinical strategies.
NordicPRO‑C3™ offers a dynamic solution by enabling longitudinal monitoring of active fibrosis remodeling, providing direct evidence of a drug’s impact on fibrotic pathways already in phase IB. By tracking changes in NordicPRO‑C3™ levels over time, researchers can assess whether a therapy is effectively reducing fibrosis, determine optimal dosing strategies, and detect early signs of treatment response.
By integrating NordicPRO‑C3™ into clinical trials and treatment protocols, drug developers and clinicians gain a powerful pharmacodynamic biomarker that validates drug efficacy, supports regulatory decision-making, and accelerates the path to precision fibrosis therapies.
NordicPRO‑C3™ is a biomarker of fibrosis formation, making it highly relevant for diseases characterized by excessive fibrosis. It has been studied and applied in a range of conditions, including, but not limited to:
Liver Diseases
Lung Diseases
Renal Diseases
Cardiovascular Diseases
Systemic Fibrotic and Autoimmune Diseases
Solid cancers
- Pancreatic cancer
- Breast cancer
- Lung cancer
- Colorectal cancer
- Melanoma
